Famotec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Famotec

Property Description
Active ingredient Famotidine
Form Tablet, Solution for injection
Pharmacological class Histamine H₂-receptor antagonist (H₂-blocker)
General purpose Reduction of excessive stomach acid
Origin Synthetic compound

What Type of Medicine is Famotec? (Identity and Classification)

Famotec is a trade name for a medicine whose active ingredient is Famotidine, a synthetic compound classified as a Histamine H₂-receptor antagonist, also known as an H₂-blocker. It is a single-ingredient product, designed for systemic administration, meaning it acts throughout the body.

The classification of Famotidine as an H₂-blocker defines its core therapeutic function and is clinically recognized for its role in controlling acid production. Famotidine belongs to the class of antiulcer agents. This chemical entity is available in two primary dosage forms: an oral tablet for ingestion and a solution for injection for intravenous (IV) administration.

Famotidine: The Core Composition and General Purpose (Composition and Benefit)

The essential substance that gives Famotec its effect is the molecule Famotidine (C8H15N7O2S2). Its general purpose is to provide relief by regulating and reducing the amount of acid produced in the stomach, which is the typical approach for managing symptoms of acid overload.

Famotidine works by executing a precise, pharmacologically confirmed targeted action on specific receptors found in the stomach lining, thereby inhibiting the signal that triggers acid production. The drug acts to decrease the amount of acid the stomach makes. This fundamental mechanism helps to lessen irritation and provides relief from discomfort caused by excessive gastric acid. By controlling and significantly decreasing this acid output, the medication's primary benefit is mitigating issues caused by pathological stomach acid secretion.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Famotec?

Possible Side Effects and Safety Information

The safety profile of Famotidine is formally defined by regulatory authorities based on clinical trials and post-marketing surveillance, classifying adverse reactions by frequency and physiological system.

Common adverse reactions, which are the most frequently documented, include Headache, Dizziness, Constipation, and Diarrhea. Less frequent reactions classified as Uncommon involve other gastrointestinal effects, such as Abdominal Discomfort, Nausea, and Vomiting, alongside general systemic effects like Fatigue.

Adverse effects are documented across multiple System-Organ Classes, including the Nervous System, Gastrointestinal System, and Skin. Rare events are also noted in official regulatory sources, including severe Hypersensitivity Reactions (e.g., Anaphylaxis) and severe dermatological conditions like Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Officially documented Serious Adverse Reactions also encompass effects on the blood system, known as Blood Dyscrasias (e.g., Agranulocytosis, Thrombocytopenia), and Hepatotoxicity (Hepatitis). These are listed due to their potential clinical significance.

Safety constraints noted in regulatory documents include the requirement for caution in specific populations. For instance, Geriatric Patients may have an increased risk of developing Central Nervous System effects such as confusion. Furthermore, caution is necessary in individuals with underlying Renal Impairment due to the risk of drug accumulation in the body, which could increase the potential for adverse effects. The reduction of gastric acid is also documented as potentially affecting the pH-dependent absorption of other medicinal products.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Famotec (Famotidine) requires immediate attention from medical professionals as officially documented in regulatory sources.

Documented Manifestations and Severe Outcomes

Overdose exposure is officially associated with specific clinical manifestations, primarily impacting the central nervous system (CNS). These include confusion, agitation, hallucinations, slurred speech, and lethargy. Systemic signs like vomiting, diarrhea, flushing, and sweating may also occur.

Serious and life-threatening outcomes are documented, notably severe CNS events like seizures and grand mal convulsions. Cardiovascular risks include the documented occurrence of arrhythmias and a risk for the heart tracing abnormality known as QT prolongation.

Population-Specific Considerations

Official regulatory information specifies that individuals with moderate to severe renal impairment and elderly patients face an increased risk of severe CNS adverse reactions due to higher systemic drug exposure.

Emergency Actions and Treatment

Treatment for overdose is strictly symptomatic and supportive because no specific antidote is known. Measures may involve continuous clinical monitoring, including an ECG, and procedures like administering activated charcoal to remove unabsorbed drug material.

Urgent medical help must be sought immediately for any suspected overdose. Call emergency services (such as 911) if the person has collapsed, experienced a seizure, or has trouble breathing.

Therapeutic Uses of Famotec

What Famotec treats: main uses and benefits

Famotec contains famotidine, a medication belonging to the class of histamine-2 (H2) receptor antagonists. It is primarily used to manage conditions related to excessive stomach acid production.

Primary Uses

  • Gastroesophageal Reflux Disease (GERD): Famotec is used to treat the symptoms of acid reflux, such as heartburn and acid regurgitation. It helps manage the irritation caused by stomach acid flowing back into the esophagus.
  • Gastric and Duodenal Ulcers: The medication is indicated for the treatment of active sores in the lining of the stomach (gastric ulcers) or the upper part of the small intestine (duodenal ulcers). It is also used as a maintenance therapy to prevent these ulcers from recurring after the initial healing process.
  • Zollinger-Ellison Syndrome: Famotec is utilized in the management of hypersecretory conditions where the stomach produces abnormally high levels of acid.
  • Erosive Esophagitis: It is used to treat and promote the healing of inflammation or sores in the esophagus caused by chronic acid exposure.

Benefits and Mechanism

Famotec works by blocking the H2 receptors located on the acid-producing cells in the stomach lining. By inhibiting these receptors, the medication reduces the total volume and concentration of gastric acid secreted during the day and night, as well as in response to food consumption.

Reduced acid levels allow the esophageal and gastrointestinal linings to heal, providing relief from discomfort and preventing further tissue damage. This reduction in acidity is beneficial for long-term symptom control and the prevention of complications associated with acid-related disorders.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Famotec?

This section outlines the population eligibility and non-eligibility for Famotec (Famotidine) strictly according to government regulatory documents.


Eligibility Scope

Category Official Regulatory Statement
Populations Contraindicated Patients with a history of serious hypersensitivity reactions to famotidine or other H2 -receptor antagonists. Neonates must not receive the injection form due to the benzyl alcohol preservative.
Age-Related Eligibility Adults are the primary eligible population. Pediatric use is established from birth (suspension) to < 17 years, but the use of tablets is not recommended in children weighing less than 40 kg.
Condition-Specific Restrictions Adults with moderate to severe renal impairment (kidney disease) require a mandatory dosage adjustment (reduction) to mitigate the risk of CNS adverse reactions. Prior evaluation for potential gastric malignancy is required before starting therapy.
Pregnancy and Lactation Use is generally not recommended unless necessary; the drug is excreted in breast milk, requiring a decision to discontinue the drug or nursing.

Eligibility Structure Summary

Regulatory documents establish the criteria for use by classifying groups as Contraindicated (absolute exclusion), Not Recommended (strong avoidance preference), or subject to Conditional Use (requiring mandatory adjustment for renal function). The safety and effectiveness for certain indications, such as in pediatric patients with renal impairment, are officially classified as not established.

What should I know about interactions with other medicines?

Famotidine (Famotec) interactions are officially documented based on two primary pharmacokinetic mechanisms. As a Histamine H₂-receptor antagonist, Famotidine significantly increases gastric pH, which reduces the systemic exposure and potential efficacy of co-administered medicines whose absorption requires an acidic environment. This category includes certain antineoplastics (e.g., Erlotinib, Acalabrutinib, Crizotinib). To manage this pH-dependent interaction, regulatory labeling requires a specific timing separation rule for agents like Erlotinib, which must be taken either two hours before or ten hours after an H₂-blocker.

A second documented mechanism involves the inhibition of drug clearance. Co-administration with Tizanidine may result in substantial increases in Tizanidine blood concentrations (a CYP1A2 substrate), leading regulatory labeling to advise that concomitant use should be avoided, if possible. Famotidine is also documented to increase the levels of Erdafitinib by decreasing its renal clearance through the OCT2 transporter. For patients with renal impairment, higher systemic exposure to Famotidine itself is noted, increasing the clinical significance of any interaction that further raises its concentration. Additionally, Antacids may decrease Famotidine absorption and should be separated by one to two hours. A pharmacodynamic additive effect is documented with agents that prolong the QTc interval.

Mechanism of Action

How Famotec Works

Famotec, a nitrogen-containing bisphosphonate, is selectively taken up by osteoclasts and inhibits the farnesyl pyrophosphate (FPP) synthase enzyme within the mevalonate pathway. This enzymatic inhibition disrupts the synthesis of key prenyl diphosphates, specifically geranylgeranyl-diphosphate (GGPP) and farnesyl-diphosphate (FPP).

These prenyl diphosphates are necessary cofactors for the post-translational modification, known as prenylation, of small GTPases (like Ras, Rho, and Rac). The resulting reduction in protein prenylation leads to the functional inactivation of these signaling proteins, which are critical for osteoclast structure, adhesion, and survival.

This downstream mechanistic cascade prevents osteoclast maturation and triggers apoptosis. The cumulative effect of these intracellular processes is the modulation of osteoclast-mediated bone resorption at the tissue level, a purely physiological consequence.

Dosage and Administration Information

Official Administration Guidelines for Famotec (Famotidine)

The use of Famotec is governed by precise instructions concerning the route, dose, frequency, and duration of therapy.

Famotidine is available for administration by two official routes: the oral route (tablet or suspension) for outpatient use and maintenance, and the intravenous (IV) route (injection/infusion). The IV form is reserved for short-term use in hospitalized patients or those temporarily unable to take oral medication.

Dosing and Frequency Patterns

Oral administration is typically dosed at 20 mg or 40 mg. For most acute conditions, the dose is taken once daily (40 mg) or twice daily (20 mg) for a defined period, such as up to 8 weeks for active ulcers. Maintenance therapy to reduce the risk of ulcer recurrence is usually 20 mg once daily for up to one year. For pathological hypersecretory conditions, the starting oral dose is typically 20 mg every 6 hours, which may be adjusted to a maximum of 160 mg every 6 hours.

Oral tablets may be taken with or without food. Once-daily doses are generally scheduled to be taken at bedtime to align with acid secretion patterns. If a dose is missed, it is advised to resume the regular schedule and not take a double dose.

Population and Procedural Adjustments

Dose adjustment is recommended for adult patients diagnosed with moderate or severe renal impairment (creatinine clearance less than 60 mL/min). This adjustment usually involves reducing the dose by half or extending the dosing interval to 36–48 hours for certain indications. For IV administration, the solution must be administered slowly, either as an injection over at least 2 minutes or an infusion over 15 to 30 minutes.

This structured use protocol ensures that the specific dosage and administration context are aligned with physiological requirements and clearance rates.

Recent Clinical Evidence

Research Evidence Overview of Studies for Famotec

The research evidence for Famotec (Famotidine) primarily relies on randomized controlled trials (RCTs) and systematic reviews. These studies focus on conditions linked to excessive stomach acid. The findings describe group patterns and observed changes in patients, but they do not provide personal predictions or clinical advice.


Evidence for Healing Stomach and Duodenal Ulcers

Clinical research has extensively studied Famotec for research exploring active ulcers found in the stomach (gastric ulcers) and the upper part of the small intestine (duodenal ulcers). Most of this research was observed in short-term randomized, controlled trials in adult populations with endoscopically confirmed ulcers.

Researchers designed these studies to measure two key outcomes: the endoscopic healing rate (whether the ulcer physically closed) and the patient-reported change in associated symptoms, such as pain or discomfort. Findings describe patterns in healing rates and symptom change across the observed patient groups. For duodenal ulcers, maintenance studies were also conducted to explore recurrence patterns.

While research examined patterns related to ulcer healing over these defined time intervals, long-term outcomes and recurrence patterns beyond one year are not as thoroughly characterized. Additionally, evidence comparing this drug with certain other pharmacological agents is less extensive in the current research landscape.


Studies for Gastroesophageal Reflux Disease (GERD)

Famotec was studied for use in patients with Gastroesophageal Reflux Disease (GERD), a condition where stomach acid flows backward into the esophagus. The evidence base includes controlled trials that measured changes in key symptoms like heartburn, and in more severe forms, the healing of physical damage (erosions) to the esophageal lining.

Research describes observations regarding the timing of symptom change relative to the healing of physical erosions. Limited information is available regarding outcomes once patients discontinue the medication. Data for the very youngest pediatric patients with complex GERD remains modest, and follow-up durations for all populations were sometimes restricted to the acute treatment phase.


What Research Gaps and Uncertainties Remain

While the body of evidence provides substantial context for the approved uses of Famotec, research highlights what is known—and what is still uncertain. Evidence for long-term use, especially beyond one year of maintenance therapy, remains an area where data are still emerging to provide comprehensive insight.

Furthermore, research exploring non-acid-related indications—such as certain respiratory virus-related illnesses—have been exploratory and findings were mixed across the published literature. Therefore, certainty remains low in these areas, and large-scale, definitive trials have not confirmed a consistent pattern of response. Research continues to explore these and other questions related to the drug's properties.

Key Studies & References

  1. Famotidine - Drug Information Portal (NIH)
  2. Famotidine: Indications, Mechanism, and Side Effects (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Famotec (FAQ)


Q: What conditions is Famotec officially indicated or approved to treat?

A: According to regulatory documents, Famotec is officially approved for conditions related to excessive stomach acid. These include the treatment of stomach (gastric) and intestinal (duodenal) ulcers, as well as symptomatic non-erosive gastroesophageal reflux disease (GERD). It is also indicated for pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

Q: Can Famotec be used for general indigestion or an occasional upset stomach?

A: Official product information states that the over-the-counter (OTC) forms of Famotec are used to relieve and prevent heartburn. This includes symptoms associated with occasional acid indigestion and sour stomach.

Q: How long does it typically take for Famotec to start relieving symptoms?

A: Based on clinical data, the medication is generally expected to begin reducing acid production within one hour after administration. Individual response times may vary.

Q: How long does the acid-reducing effect of Famotec generally last?

A: Official pharmacological data indicates that the acid-reducing effect of Famotec generally lasts for about 10 to 12 hours following a single dose. This duration is consistent regardless of the dosage form.

Q: What is the main difference between Famotec and a PPI like omeprazole?

A: Famotec is classified as a Histamine H2-receptor antagonist, which works to quickly lower the amount of acid produced in the stomach. Medicines like omeprazole are Proton Pump Inhibitors (PPIs) that block the final stage of acid production. PPIs may take longer to reach full effect but are often associated with longer-lasting acid suppression.

Q: Is the generic version of Famotec equivalent to the brand-name product?

A: Regulatory bodies, such as the FDA, require that generic versions of a drug must meet the same standards for quality, strength, purity, and stability as the original brand-name product. Therefore, generic Famotidine must meet regulatory standards that demonstrate it is equivalent to the brand-name product.

Q: Can Famotec be taken to prevent symptoms before consuming a trigger food?

A: Yes, the over-the-counter product information confirms that Famotec can be used to prevent symptoms. For prevention, the label information specifies that the dose is generally taken 10 to 60 minutes before consuming food or beverages that may cause heartburn.

Q: Is it true that the effectiveness of Famotec can decrease over time with regular use?

A: Clinical experience with H2 blockers, the class of drugs Famotec belongs to, suggests that the body may develop tolerance to the effects over time. This means that consistent, regular use is sometimes associated with a gradual decrease in the medication's effectiveness.

Q: Does official information suggest long-term use of Famotec causes vitamin B12 deficiency?

A: Clinical studies suggest that extended use of acid-reducing medicines may be associated with reduced absorption of certain nutrients, including Vitamin B12. This is because stomach acid is required for the proper absorption of B12.

Q: What should be done if symptoms persist or worsen after taking Famotec for a specific period?

A: The over-the-counter product warnings indicate that one should discontinue use if heartburn symptoms persist, worsen, or if the product is needed for more than 14 days. Regulatory guidance states that a healthcare professional should be consulted if these conditions occur.

Q: Can alcohol consumption interfere with the intended effects of Famotec?

A: While official documents do not list alcohol as a direct contraindication, information indicates that Famotec may increase the body's rate of alcohol absorption. This may result in changes to blood alcohol levels and the effects experienced from the alcohol consumed.

Q: Is there a distinction between prescription and over-the-counter Famotec regarding duration of effect?

A: No. The duration of the drug's acid-reducing effect is determined by its inherent pharmacological properties and chemical half-life. This effect remains consistent across both the prescription and over-the-counter formulations of the active ingredient.

Q: Why do some official warnings mention checking for bloody or black stools when using Famotec?

A: Official product warnings advise checking for bloody or black (tarry) stools because these are potential signs of a more serious underlying gastrointestinal condition, such as internal bleeding or an ulcer. Regulatory guidance indicates that a medical evaluation is warranted if these symptoms appear.

Q: Can taking Famotec affect the activity of aspirin or other NSAID pain relievers?

A: Famotec does not typically interfere with the anti-inflammatory or pain-relieving activity of NSAIDs (Nonsteroidal Anti-inflammatory Drugs) like aspirin. However, it is sometimes used alongside NSAIDs specifically to reduce the risk of gastrointestinal ulcers that these pain relievers can cause.

Q: Is it acceptable to crush or split the tablet formulation of Famotec?

A: According to the official directions, Famotec tablets should be swallowed whole with water. The tablets are typically not intended to be crushed, split, or chewed, unless specific instructions have been given by a healthcare professional.

Q: How is Famotec different from a simple antacid tablet?

A: Famotec, an H2 blocker, works by reducing the production of stomach acid at the source over a period of hours. In contrast, antacids work by immediately neutralizing the existing acid in the stomach. This difference in mechanism results in a difference in onset and duration of relief.

Q: Does using Famotec for a long time increase the risk of any cognitive issues, according to official data?

A: Official safety information notes a specific caution regarding Central Nervous System (CNS) effects, such as confusion or delirium. This increased risk is primarily documented in elderly patients and in individuals who have kidney impairment, where the drug can accumulate.

Q: Are there any common over-the-counter medicines or supplements that can interact with Famotec?

A: Official documents contain a precaution to discuss all nonprescription medicines and supplements with a healthcare provider. This is a precaution because many over-the-counter products, including certain vitamins, supplements, and herbal products, have the potential to interact with Famotec.

Q: Does taking Famotec require any special dietary instructions or food timing?

A: According to regulatory drug information, Famotec can generally be taken with or without food. Official guidance is to continue a normal diet unless a healthcare professional provides specific dietary instructions.

Q: Is it safe to take Famotec and a calcium-containing antacid at the same time?

A: Official interaction data indicates that taking antacids, including calcium-containing ones, at the same time as Famotec may decrease the absorption of Famotec, potentially lowering its effectiveness. For this reason, a time separation of one to two hours between taking Famotec and an antacid is often advised in the product information.

Q: What is the recommended maximum duration for using over-the-counter Famotec products?

A: The official warnings for over-the-counter (OTC) Famotec products state a specific time limit. The product information states that the medicine is not intended for use longer than 14 consecutive days unless directed by a healthcare professional.

Q: Is Famotec an appropriate option for people who have existing kidney or liver conditions?

A: Patients with moderate to severe kidney impairment (renal impairment) are subject to required dosage adjustments outlined in regulatory documents, due to the potential for drug accumulation and increased risk of side effects. Official guidance advises consulting a healthcare professional for guidance regarding Famotec use if you have existing kidney or liver conditions.

Q: Why is Famotec available in different strengths, such as 10 mg and 20 mg?

A: Famotec is available in various strengths and dosing schedules because the different acid-related conditions it treats require different treatment regimens. For example, the short-term treatment of an active ulcer often requires a different dose than long-term maintenance therapy.

Q: What are the available dosage forms of Famotec (e.g., tablet, liquid, chewable)?

A: Official product information confirms that Famotidine is available in several dosage forms. These include an oral tablet, a liquid oral suspension, and a solution for intravenous injection. Chewable tablets are also available, often as part of an over-the-counter combination product.

Q: Is Famotec used to manage conditions that cause excessive stomach acid, like Zollinger-Ellison syndrome?

A: Yes. Regulatory documents indicate that one of the official indications for Famotec is the treatment of pathological hypersecretory conditions. This category includes severe acid-secreting disorders such as Zollinger-Ellison syndrome.

Q: What type of drug is Famotec chemically similar to, aside from its other brand names?

A: Famotec is classified as a Histamine H2-receptor antagonist, or H2 blocker. This drug class includes other chemically similar medicines that function by the same mechanism, such as cimetidine and ranitidine.

Q: Can a person take Famotec if they have a known allergy to other H2 blockers?

A: Official regulatory information advises that Famotec should not be used if a person has a known history of a serious allergic reaction. This caution applies to the active ingredient, Famotidine, and any other medicine belonging to the H2 receptor antagonist class of drugs.

Q: Are there special warnings regarding taking Famotec if a person has a history of heart rhythm problems?

A: Yes. Regulatory precautions advise patients to inform their healthcare provider if they have a history of heart rhythm problems, such as QT prolongation. Caution is required because there is documented potential for the drug to affect heart rhythm.

Q: Is Famotec approved for both preventing and actively treating acid reflux symptoms?

A: Yes. Official product labeling for the over-the-counter formulation confirms that it is approved for both the active relief (treatment) of heartburn symptoms and the prevention of symptoms when taken before consuming trigger foods or drinks.

Q: Can Famotec interfere with the absorption of certain antifungals or HIV medications?

A: Yes. Famotec works by raising the stomach's pH level (making it less acidic). Official interaction data indicates this change can lower the absorption and effectiveness of co-administered medicines that require an acidic environment, such as certain antifungals or HIV medications.

Q: Is Famotec the active ingredient in any other brand names besides the most common ones?

A: Yes. Famotidine is the common active ingredient found in numerous heartburn relief products. It is the core component of other brand names, including Pepcid AC and Zantac-360.

Q: What is the lowest age at which a child can use over-the-counter Famotec products?

A: The official directions for the over-the-counter product specify age limits. The label states that a healthcare professional must be consulted before the product is administered to children under 12 years of age.

How should Famotec be stored and disposed of?

How to Store and Dispose of Famotidine (Famotec)

Famotidine must be stored according to its dosage form to maintain stability and effectiveness. All forms of Famotidine must be kept out of the sight and reach of children.


Storage Requirements

Famotidine oral tablets require storage at Controlled Room Temperature (20^circ to 25 C) and must be protected from moisture and light. The unmixed solution for injection requires refrigeration (2^circ to 8 C) and protection from light. If the injection is diluted for intravenous use, it must be used within 48 hours if refrigerated.


Disposal

Unused or expired Famotidine, including tablets and injection vials, must be disposed of in accordance with local regulations. For the injection, used needles and syringes require specific sharps disposal protocols as advised by a healthcare provider.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Famotec found in:

A-Z Index: